CMAB vs IMAB in Metastatic Prostate Cancer
Phase 4
Withdrawn
- Conditions
- Metastatic Prostate Cancer
- Registration Number
- NCT00255268
- Lead Sponsor
- AstraZeneca
- Brief Summary
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
- Histological diagnosis of D2 of Adenocarcinoma,
- Naivety to treatment
- Valuable bone metastasis
Exclusion Criteria
- Hematological, liver or renal toxicity Grade IV
- Severe and active infections
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method Safety Quality of Life
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of goserelin and bicalutamide in androgen receptor signaling inhibition for metastatic prostate cancer?
How does continuous maximum androgen blockade compare to intermittent protocols in terms of progression-free survival in hormonal naïve metastatic prostate cancer patients?
Which biomarkers are associated with response to goserelin-bicalutamide combination therapy in androgen-dependent prostate cancer subtypes?
What are the potential adverse events and management strategies for long-term use of goserelin and bicalutamide in prostate cancer treatment?
How does the goserelin-bicalutamide regimen compare to other androgen deprivation therapies like leuprolide or enzalutamide in metastatic prostate cancer management?
Trial Locations
- Locations (1)
Research Site
🇲🇽Mexico City, Mexico
Research Site🇲🇽Mexico City, Mexico